Cumberland Pharmaceuticals is on a mission to improve patient care through the delivery of high-quality pharmaceutical products. Vibativ is an FDA-approved treatment for certain serious bacterial infections with proven efficacy against difficult-to-treat Gram-positive infections. Caldolor is the first injectable approved in the U.S. to manage pain in adults and pediatric patients and has been shown to help reduce the need for opioids.
With the addition of our Phase II candidate for patients with Duchenne muscular dystrophy, we are developing new medicines for the future. Learn more about recent company developments from Cumberland Pharmaceuticals' Founder and Chief Executive Officer A.J. Kazimi.
With the addition of our Phase II candidate for patients with Duchenne muscular dystrophy, we are developing new medicines for the future. Learn more about recent company developments from Cumberland Pharmaceuticals' Founder and Chief Executive Officer A.J. Kazimi.
Services
For over 20 years, Cumberland Pharmaceuticals has improved the quality of patient care through the delivery of high-quality prescription medicines. With a focus on underserved niche markets, including hospital acute care and gastroenterology, we supply products that offer distinct advantages over prior treatments.
These are the four key elements of our growth strategy. Cumberland Pharmaceuticals is a unique company with quality products that deliver real patient solutions every day. Our strategy involves maximizing the potential of our existing brands while continuing to build a portfolio of differentiated products.
Mr. Kazimi founded our company in 1999 and has served as the Chairman of our Board of Directors and Chief Executive Officer since inception. His career includes 30 years in the biopharmaceutical industry. At Cumberland, he has overseen the development and FDA approval of the company's Acetadote and Caldolor brands, while also leading the acquisition of the Company's five other commercial products.
Cumberland Emerging Technologies (CET) provides access to a long term pipeline of innovative, biopharmaceutical product candidates. CET was established as a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University and the state of Tennessee to identify innovative product candidates and advance them from the laboratory to the marketplace.
Reviews
Be the first to review Lakeside Building Maintenance.
Write a Review
